[Skip to Content]
[Skip to Content Landing]
Views 13,616
Citations 0
JAMA Clinical Guidelines Synopsis
August 27, 2020

Ulcerative Colitis in Adults

Author Affiliations
  • 1Yale University, New Haven, Connecticut
  • 2University of Chicago, Chicago, Illinois
  • 3University of Washington, Seattle
JAMA. 2020;324(12):1205-1206. doi:10.1001/jama.2020.11583

Ulcerative colitis is a chronic, immune-mediated inflammatory disease that affects the large intestine. Disease severity is determined by patient-reported outcomes, inflammatory burden as measured by endoscopic assessment and markers of inflammation, disease course, and how the disease affects patients. Management of ulcerative colitis is increasingly complex with new treatments available and improved understanding of the disease’s pathophysiology.

This guideline was developed by the ACG. The writing committee included board-certified gastroenterologists with expertise in diagnosis and management of ulcerative colitis. The guideline lists potential conflicts of interest but does not state how the disclosed conflicts were managed (Table).1 The literature searches used were limited to primary clinical trials, meta-analyses, systemic reviews, and prior guidelines. Quality of evidence was assessed using GRADE. A final review was conducted with the board of trustees, the practice parameters committee, and the American Journal of Gastroenterology prior to publication.